Welcome to tagrissoandme.co.uk*

This website is intended only for UK patients who have been prescribed TAGRISSO® (osimertinib)

*This website has been produced and funded by AstraZeneca UK.

I am not a UK TAGRISSO patient
This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib)
Logo
☰
  • Home
  • Know your lung cancer
    • Lung cancer diagnosis
    • Biomarker Testing
  • About osimertinib
    • What is osimertinib?
    • How to take osimertinib
  • Managing side effects
    • Potential side effects
    • Tips on managing side effects
  • Treatment for your lung cancer stage
  • Support
    • Lung cancer support organisations
    • Resources
    • FAQs
 

Contact us

 

The information on this website is not a substitute for medical advice. If you have any questions about your condition or the treatment you have been prescribed, please speak to a healthcare professional.


 For medical enquiries about AstraZeneca products (including questions on how to take your medicine, to report a side effect or make a complaint), you can also call AstraZeneca's Medical Information team on: 0800 783 0033. Lines are open Monday to Friday, from 9am to 5pm.

 

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.

 

Side effects can also be reported to AstraZeneca in the following ways:

Online https://contactazmedical.astrazeneca.com/
Email Medical.InformationUK@astrazeneca.com
Telephone 0800 783 0033

 

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get, see http://yellowcard.mhra.gov.uk/ for how to report side effects.

 

GB-73019   I  DOP: January 2026

 

This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib), which is indicated after surgery in adults with stage 1B-3A NSCLC with a particular EGFR mutation, and also in locally advanced or metastatic NSCLC with a particular EGFR mutation. It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.

Reporting side effects

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of medicines.

Side effects can also be reported to AstraZeneca in the following ways:

Online: https://contactazmedical.astrazeneca.com

Email: Medical.InformationUK@astrazeneca.com

No imagery of real patients has been used on this site.

  • Legal Notice and Terms of Use
  • Privacy Notice
  • Cookie Policy
  • Contact us

© AstraZeneca 2026. All rights reserved

GB-76796| DOP: October 2026

AstraZeneca logo